AngioDynamics Expands NanoKnife EU Indications and Schedules Leerink Presentation
AngioDynamics expanded its NanoKnife ablation system’s CE approval across Europe to include liver, pancreas, kidney and prostate tumors, boosting its oncology device portfolio’s addressable market. The company also confirmed it will present its strategic outlook and recent clinical data at the Leerink Partners Global Healthcare Conference later this quarter.
1. EU NanoKnife Indication Expansion
AngioDynamics has received updated CE certification for its NanoKnife electroporation system to treat tumors in the liver, pancreas, kidney and prostate, expanding the device’s approved use across all 27 EU member states. This regulatory milestone unlocks new commercial opportunities and supports planned launches in key European markets later this quarter.
2. Leerink Healthcare Conference Presentation
The company will deliver a presentation at the upcoming Leerink Partners Global Healthcare Conference to showcase recent clinical outcomes and outline its oncology segment growth strategy. Management aims to detail trial results underpinning the expanded indications and provide preliminary revenue forecasts for NanoKnife deployments in 2026.